Last reviewed · How we verify

standard dose amoxicillin/clavulanate

Albany Medical College · FDA-approved active Small molecule

Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes that would otherwise destroy amoxicillin.

Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes that would otherwise destroy amoxicillin. Used for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.

At a glance

Generic namestandard dose amoxicillin/clavulanate
SponsorAlbany Medical College
Drug classBeta-lactam antibiotic with beta-lactamase inhibitor
TargetPenicillin-binding proteins (PBPs); bacterial beta-lactamase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanate is a beta-lactamase inhibitor that protects amoxicillin from degradation by bacterial beta-lactamase enzymes, extending the spectrum of activity to include beta-lactamase-producing organisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: